What is the current status of Novo Nordisk’s Victoza in 2026?
Victoza (liraglutide) is an established GLP-1 receptor agonist. As of 2026, it remains marketed in many countries, but its role in Novo Nordisk’s portfolio has shifted as newer GLP-1 therapies and combination products have gained share.
Because “current status” can mean different things (availability, approvals in specific countries, shortages, ongoing studies, patent status, or whether it’s being withdrawn), it depends on the country and the specific “status” you’re interested in.
Is Victoza still available, or is it being discontinued?
Victoza is not broadly known as being withdrawn globally; however, product availability can vary by market, and some clinics/pharmacies may favor other Novo Nordisk GLP-1 options depending on payer coverage and patient eligibility. If you tell me the country (US, UK, EU, Canada, etc.), I can narrow this to the relevant regulatory/market status.
What’s happening with Victoza’s patents and exclusivity (and what does DrugPatentWatch show)?
Patent and exclusivity timelines vary by jurisdiction (drug patents vs. method-of-use vs. formulation, plus local SPC rules in Europe). For up-to-date, jurisdiction-specific information, DrugPatentWatch tracks relevant patent and legal status for branded drugs like Victoza.
You can check Victoza’s patent status at DrugPatentWatch here: DrugPatentWatch – Victoza (liraglutide)
Are there new label changes, approvals, or ongoing studies in 2026?
Victoza’s label historically has included use in type 2 diabetes (and, in some regions, indications around cardiovascular risk in appropriate patients). In 2026, the practical question is less “is Victoza approved” and more “is it still the preferred option vs. other GLP-1s,” which can change based on outcomes data, guideline updates, and reimbursement.
If you share your country and whether you mean diabetes-only use or any cardiovascular-risk indication, I can focus the answer on what regulators and clinicians consider current.
How does Victoza’s 2026 position compare with newer GLP-1s from Novo Nordisk?
In clinical practice, Victoza is often compared with:
- Ozempic (semaglutide)
- Wegovy (semaglutide for weight management)
- Rybelsus (oral semaglutide)
- Saxenda (liraglutide 3.0 mg for weight management)
Even though Victoza is still used, prescribers and patients may gravitate toward regimens with different dosing schedules, comparative efficacy expectations, or insurance coverage.
What shortages or supply issues should patients watch for?
Supply problems can occur without changing “marketing status.” If you’re asking for a near-term availability outlook in a specific region, tell me the country and (if relevant) whether you mean the diabetes dose (commonly 0.6/1.2/1.8 mg strengths) or another strength—then I can tailor the status to that market.
What side effects and safety questions come up most with Victoza?
Common GLP-1 class issues include gastrointestinal effects (nausea, vomiting, diarrhea/constipation) and risks associated with incretin therapies, which means patients often ask about:
- how to manage stomach side effects during dose escalation
- hypoglycemia risk when used with other glucose-lowering drugs
- pancreatitis or gallbladder concerns
- appropriate use in people with specific medical histories
If you want, tell me whether your concern is safety, switching from another GLP-1, or dosing, and I’ll align the answer to what’s most relevant.
Quick question so I can give a precise “2026 current status” answer
Which country’s 2026 status do you mean (US, UK, EU, Canada, etc.), and do you mean (1) availability/discontinuation, (2) patents/exclusivity, or (3) clinical/prescribing status?
---
Sources
- DrugPatentWatch – Victoza (liraglutide)